Test the efficacy of your compound(s) in a panel of 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer. Our advanced screening capabilities include:

• Direct measurement of cell viability with an image-based viability readout
• High-throughput 3D assay format
• Test any number of compounds, with no minimum number of models to enroll
• High-dose quality with 10-point dose-response curves per compound
• Inclusive of IC₅₀ determination and heatmap generation

Accelerate your KRAS drug development with our comprehensive portfolio. Identify promising leads and understand compound mechanism of action to investigate and develop novel therapies. Book a consultation now!

KRASmut Panel Features

• Largest commercially available KRASmut PDO panel, with 25 models that represent pivotal KRAS mutants including G12A, G12D, G12V, G13D and many others
• Rigorously characterized with readily available RNA or DNA sequencing data
• Diverse models encompassing both primary and metastatic tumors, with the ability to test off-tumor toxicities with matched normal organoids

Applying Our KRASmut PDO Screen

Our meticulously designed KRASmut panel was instrumental in developing a clinical candidate using organoid technology targeting head & neck cancer. Discover our proof-of-concept study and learn how PDOs can be used to accelerate your preclinical therapeutic development.